Company intelligence / Profile preview

ANTIÁN

Miami, Florida, USA

Ownership: Private
Development stage: Other

Overview

Antian is a Miami-based biotechnology company developing a platform for long-acting allergy treatments. The company's mission is to provide "one-and-done" relief for common allergies, such as peanut, cat, and grass allergies, through a single therapeutic dose. Their technology focuses on engineering antibodies with significantly extended half-lives to provide years of protection from allergic reactions. Antian is currently in the pre-clinical stage and was part of the Y Combinator Winter 2022 cohort, aiming to transform the management of chronic allergic conditions.

Therapeutic areas: Immunology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Beyond the preview

Go deeper on ANTIÁN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANTIÁN.

Explore the full profile